ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

The Oncology Institute of Hope and Innovation Expands Research Partnership with Helios Clinical Across Markets, Enhancing Access to Cutting-Edge Cancer Trials

CERRITOS, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), a pioneer in value-based community oncology care, is proud to announce an enterprise-wide expansion of its strategic partnership with Helios Clinical Research, a nationally recognized research site network. This initiative builds upon a successful collaboration in Florida and reflects TOI’s ongoing commitment to integrating clinical research into community oncology settings.

“Expanding our research collaboration with Helios Clinical is a natural next step,” said Daniel Virnich, MD, CEO at TOI. “They’ve proven to be a highly capable partner, helping us streamline study activation, accelerate enrollment, and reduce operational burden on our sites. This move allows us to scale our research infrastructure much more quickly while staying laser-focused on patient care.”

Strategic Benefits of the Partnership:

  • Expanded Access to Clinical Trials: Patients will gain greater access to leading-edge therapies through trials supported by Helios’ centralized operations and outreach model.
  • Enhanced Trial Performance: Sponsors benefit from streamlined startup processes, optimized patient matching, and unified oversight.
  • Scalable Infrastructure: Helios provides regulatory, recruitment, and operational support, enabling TOI’s clinicians to focus on delivering world-class care while expanding their research footprint.
  • Equity in Oncology Research: Both organizations share a commitment to enrolling diverse and underrepresented patient populations, advancing health equity in oncology care.

“This isn’t just about geographic growth,” said Yale Podnos, MD, Chief Medical Officer at TOI. “It’s about ensuring that clinical research becomes a routine, integral part of patient care in every market we serve.”

About The Oncology Institute

Founded in 2007, TOI is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of over 1.8 million patients including clinical trials, transfusions, and other services traditionally associated with the most advanced care delivery organizations. With over 120 employed clinicians and more than 700 teammates in over 70 clinic locations, TOI is changing oncology for the better. For more information, visit www.theoncologyinstitute.com

About Helios Clinical Research
Helios Clinical Research is a full-service site network known for its integrated, tech-forward approach to clinical trial execution. With expertise in oncology and a national footprint, Helios partners with leading healthcare organizations to bring high-performing, patient-first research capabilities into real-world care settings.

Contacts

Media

The Oncology Institute, Inc.
marketing@theoncologyinstitute.com

Investors

Solebury Strategic Communications
investors@theoncologyinstitute.com


Primary Logo

Recent Quotes

View More
Symbol Price Change (%)
AMZN  248.40
+3.99 (1.63%)
AAPL  269.43
+0.96 (0.36%)
AMD  243.98
+10.44 (4.47%)
BAC  53.42
+0.22 (0.41%)
GOOG  290.59
+10.89 (3.89%)
META  631.76
+10.05 (1.62%)
MSFT  506.00
+9.18 (1.85%)
NVDA  199.05
+10.90 (5.79%)
ORCL  240.83
+1.57 (0.66%)
TSLA  445.23
+15.71 (3.66%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.